5-(3,4-difluorophenyl)-1H-tetrazole | 874773-53-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(3,4-difluorophenyl)-1H-tetrazole
• 英文别名: 5-(3,4-difluorophenyl)-2H-tetrazole
• CAS: 874773-53-2
• 化学式: C₇H₄F₂N₄
• 分子量: 182.132
• InChiKey: OPJVXMFUPHECKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3,4-difluorophenyl)-1H-tetrazole 在 sodium ethanolate 、 1-丙基磷酸酐 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 N-(1-cyclohexyl-3-methyl-1H-pyrazol-5-yl)-2-(5-(3,4-difluorophenyl)-2H-tetrazol-2-yl)acetamide
  参考文献：
  名称：

  Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

  摘要：

  The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

  DOI：

  10.1016/j.bmcl.2019.01.027
• 作为产物：
  描述：

  3,4-二氟苯腈 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以80%的产率得到5-(3,4-difluorophenyl)-1H-tetrazole
  参考文献：
  名称：

  Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

  摘要：

  The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.

  DOI：

  10.1016/j.bmcl.2019.01.027

文献信息

• CuFe2O4Nanoparticle Mediated Method for the Synthesis of 5-Substituted 1H-Tetrazoles from (E)-Aldoximes
  作者：Ravi Kumar Akula、Chandra S. Adimulam、Sathaiah Gangaram、Raju Kengiri、Narsaiah Banda、Shanthan R. Pamulaparthy

  DOI：10.2174/1570178611666140210213157

  日期：2014.4

  A strategy for the synthesis of 5-substituted 1H-tetrazoles from various (E)-aldoximes and sodium azide was adopted using copper ferrite nanoparticles as a reusable catalyst.

  使用铜铁氧体纳米颗粒作为可重复使用的催化剂，采用了一种从各种（E）-醛肟和叠氮化钠合成5-取代的1H-四氮唑的策略。
• [EN] AZETIDINES AS EP2 ANTAGONISTS<br/>[FR] AZÉTIDINES
  申请人：PFIZER LTD

  公开号：WO2009063365A1

  公开（公告）日：2009-05-22

  The present invention relates to a class of EP2 antagonistazetidinesof general formula (I), wherein the variables and substituents are as defined herein,and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata)and to intermediates usefulin their synthesis and to compositions containing them.

  本发明涉及EP2拮抗剂的一类通用式(I)的氮杂环丁烷化合物，其中变量和取代基如本文所定义，特别是EP2拮抗剂化合物，以及它们在医学上的应用，特别是在治疗子宫内膜异位症和/或子宫肌瘤（平滑肌瘤）方面，以及在其合成中有用的中间体和含有它们的组合物。
• Azetidines As EP2 Antagonists
  申请人：Skerratt Sarah Elizabeth

  公开号：US20100256109A1

  公开（公告）日：2010-10-07

  The present invention relates to a class of EP2 antagonistazetidines of general formula (I), wherein the variables and substituents are as defined herein, and especially to EP2 antagonist compounds, to their use in medicine, particularly in the treatment of endometriosis and/or uterine fibroids (leiomyomata) and to intermediates usefulin their synthesis and to compositions containing them.

  本发明涉及一类EP2拮抗剂氮杂环丙烷，其通式为（I），其中变量和取代基的定义如本文所述，特别是EP2拮抗剂化合物，它们在医学上的用途，特别是在治疗子宫内膜异位症和/或子宫肌瘤（平滑肌瘤）方面的用途，以及在其合成过程中有用的中间体和含有它们的组合物。